查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938844

局部進行性胰臟癌市場－全球產業規模、佔有率、趨勢、機會及預測（治療方法、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年）

Locally Advanced Pancreatic Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Route of administration, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球局部晚期胰臟癌市場預計將從 2025 年的 9.3873 億美元成長到 2031 年的 16.8033 億美元，複合年成長率為 10.19%。

局部晚期胰臟癌 (LAPC) 指的是腫瘤局限於胰臟及其鄰近組織，並侵犯主要血管，導致在未進行疾病抑制的情況下無法進行手術切除的惡性腫瘤階段。全球人口老化加劇以及高解析度診斷成像技術的進步是推動該市場成長的主要因素，這些技術能夠早期、準確地檢測血管侵犯。此外，新輔助化療通訊協定的臨床應用日益廣泛，旨在將無法切除的腫瘤轉化為可手術治療的選擇，除了更廣泛的技術發展外，也是推動市場成長的重要因素。

市場概覽
預測期 2027-2031
市場規模：2025年 9.3873億美元
市場規模：2031年 16.8033億美元
複合年成長率：2026-2031年 10.19%
成長最快的細分市場 免疫療法
最大的市場 北美洲

儘管取得了這些進展，但由於診斷延遲和疾病本身的侵襲性生物學特性，該領域仍面臨著許多重大障礙，嚴重限制了有效干預的治療機會。近期統計數據也印證了這項持續的臨床挑戰：美國癌症協會預測，到2025年，美國將新增約67,440例胰臟癌病例。如此高的發病率，加上疾病的快速進展，為長期治療方案的維持和市場的持續擴張帶來了巨大挑戰。

市場促進因素

對腫瘤學研發投入的增加，正透過加速發現新的治療靶點，從根本上改變局部晚期胰臟癌的治療模式。私人機構和慈善機構正積極資助應對長期挑戰的項目，例如胰腺癌緻密的間質組織和抗藥性，從而推動那些往往被傳統資金籌措方式忽視的高風險、高回報研究。例如，2024年8月，盧斯特加滕基金會宣布津貼1,070萬美元，用於加速早期檢測和藥物研發計劃，這項資金投入對於將實驗性化合物轉化為實際臨床應用至關重要。

同時，支持性的法規結構和孤兒藥資格認定為製藥公司提供了重要的商業性獎勵，促使其專注於這種高死亡率適應症。這些認定加速了針對治療選擇有限的進行性惡性腫瘤的有前景藥物的臨床開發，有效降低了市場進入門檻。一個顯著的例子是，FDA於2024年10月核准新型RAS標靶藥物IMM-1-104孤兒藥資格認定，先前數據顯示該藥物的整體緩解率達40%。鑑於該疾病帶來的巨大負擔，這些激勵措施至關重要：根據歐洲獎勵癌症協會2024年的估計，到2025年，全球將有564,930人被診斷出患有胰腺癌。

市場挑戰

局部晚期胰臟癌的侵襲性生物學特性，以及確診時往往已處於晚期的高發生率，構成了阻礙市場成長的重大障礙。由於這種惡性腫瘤通常在無特異性症狀的情況下進展，患者就診時往往已出現廣泛的血管侵犯，導致無法即時進行手術治療，並顯著限制了治療機會。這種限制縮短了藥物治療的療程，並減少了每位患者的總治療量。此外，由於疾病進展迅速，即使確診後，臨床病情惡化也常常限制了持續輔助性治療的機會，從而限制了長期照護週期產生收入。

死亡率統計數據進一步凸顯了這個限制，顯示建立穩定的患者群體十分困難。根據美國癌症協會估計，2024年美國將有51,750人死於胰臟癌。如此高的死亡率阻礙了患者群體的積累，而這對於顯著的市場成長至關重要。因此，與其他存活率較高的腫瘤亞專科相比，患者快速更換限制了長期治療策略的商業性潛力。

市場趨勢

KRAS和NRG1融合基因標靶治療的出現，透過解決以往被認為「無法治療」的分子促進因素，正在重新定義臨床治療。與普通化療不同，這些藥物能夠選擇性地抑制致癌性訊號，為攜帶特定突變的患者提供治療選擇。新型RAS選擇性抑制劑展現持久的療效，充分體現了這種精準性。例如，2024年10月，Revolution Medicines公司報告稱，其藥物RMC-6236在既往接受過治療且攜帶RAS突變的胰腺導管腺癌患者中，實現了14.5個月的中位總生存期，凸顯了治療模式正朝著個體化方向發展，以改善不同分子亞型患者的生存結局。

同時，腫瘤電場治療（TTFields）技術的進步帶來了一種非侵入性治療方法，它能在不引起全身毒性的情況下干擾癌細胞分裂。這項技術正擴大與標準化療聯合應用，以提高無法手術切除病例的療效，近期數據顯示生存率的提高也證實了這一點。根據Novocure公司於2024年12月公佈的III期PANOVA-3試驗結果，接受TTFields合併化療的患者中位總生存期為16.20個月，而僅接受化療的患者中位總生存期為14.16個月。這確立了基於器械的治療方法作為現代多模式治療方法的重要組成部分的地位。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球局部進行性胰臟癌市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療方法（化療、免疫療法、分子標靶療法、放射線治療、手術）
    • 給藥途徑（口服、注射、其他）
    • 按最終使用者（醫院/診所、門診護理中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美局部進行性胰臟癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲局部進行性胰臟癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區局部進行性胰臟癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲局部進行性胰臟癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲局部進行性胰臟癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球局部進行性胰臟癌市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Getwell
  • Ipsen Biopharmaceuticals, Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Genentech USA, Inc.
  • AstraZeneca Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17550

The Global Locally Advanced Pancreatic Cancer Market is projected to expand from USD 938.73 Million in 2025 to USD 1680.33 Million by 2031, registering a compound annual growth rate of 10.19%. Locally Advanced Pancreatic Cancer (LAPC) is defined as a malignancy stage where the tumor remains confined to the pancreas and immediate structures but encases major blood vessels, rendering it surgically unresectable without prior downstaging. The market is chiefly sustained by the growing global geriatric population and advancements in high-resolution diagnostic imaging, which facilitate earlier and more accurate detection of vascular involvement. Additionally, the rising clinical implementation of neoadjuvant chemotherapy protocols aimed at transforming unresectable tumors into surgical candidates acts as a primary catalyst for market growth, separate from broader technological developments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 938.73 Million
Market Size 2031USD 1680.33 Million
CAGR 2026-203110.19%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

Despite these advancements, the sector encounters significant hurdles due to late-stage diagnoses and the aggressive biological nature of the disease, which severely restricts the therapeutic window for effective intervention. This persistent clinical challenge is supported by recent statistics; the American Cancer Society projects that approximately 67,440 individuals in the United States will be diagnosed with pancreatic cancer in 2025. Such elevated incidence rates, combined with rapid disease progression, create substantial obstacles to maintaining long-term treatment regimens and achieving sustained market expansion.

Market Driver

Increasing investments in oncology research and development are fundamentally transforming the therapeutic landscape for locally advanced pancreatic cancer by driving the discovery of novel therapeutic targets. Private and philanthropic entities are aggressively funding initiatives to address historical challenges related to the disease's dense stroma and drug resistance, enabling high-risk, high-reward studies that traditional funding might bypass. For example, the Lustgarten Foundation announced in August 2024 that it awarded $10.7 million in new grants specifically to accelerate projects focused on early detection and new drug development, a financial commitment essential for advancing experimental compounds into viable clinical options.

Concurrently, supportive regulatory frameworks and Orphan Drug Designations provide critical commercial incentives for pharmaceutical companies to focus on this high-mortality indication. These designations expedite the clinical development of promising agents intended for aggressive malignancies with few options, effectively lowering market entry barriers. A notable example occurred in October 2024, when the FDA granted orphan status to the novel RAS-targeting agent IMM-1-104 following data showing a 40% overall response rate; such incentives are vital given the immense disease burden, with Digestive Cancers Europe estimating in 2024 that 564,930 individuals globally will be diagnosed with pancreatic cancer by 2025.

Market Challenge

The aggressive biological nature of locally advanced pancreatic cancer, combined with frequent late-stage diagnosis, presents a major obstacle that directly impedes market growth. Because the malignancy often develops without specific symptoms, patients frequently present with extensive vascular encasement that precludes immediate surgical options and severely limits the therapeutic window. This constraint shortens the duration for administering pharmaceutical interventions, thereby reducing the total volume of therapeutics used per patient; furthermore, the rapid progression of the disease means that even when identified, the opportunity for sustained neoadjuvant treatment is often curtailed by clinical deterioration, restricting revenue generation from long-term care cycles.

This limitation is further underscored by mortality statistics that highlight the difficulty in establishing a stable patient base. According to the American Cancer Society, an estimated 51,750 deaths were attributed to pancreatic cancer in the United States in 2024. Such high attrition rates prevent the accumulation of a prevalent population necessary to drive significant market growth. Consequently, the rapid turnover within the patient pool limits the commercial potential of prolonged therapeutic strategies compared to other oncology sectors characterized by higher survival rates.

Market Trends

The emergence of KRAS and NRG1 fusion targeted therapies is redefining clinical management by addressing molecular drivers that were previously considered undruggable. Unlike generic chemotherapy, these agents selectively inhibit oncogenic signaling, offering options for patients with specific mutations, a precision exemplified by new RAS-selective inhibitors showing durable activity. For instance, Revolution Medicines reported in October 2024 that their agent RMC-6236 achieved a median overall survival of 14.5 months in patients with previously treated pancreatic ductal adenocarcinoma harboring RAS mutations, highlighting a shift toward personalized interventions that improve survival outcomes in distinct molecular subtypes.

Simultaneously, the advancement of Tumor Treating Fields (TTFields) introduces a non-invasive modality that disrupts cancer cell division without causing systemic toxicity. This technology is increasingly integrated with standard chemotherapy to enhance efficacy in unresectable cases, a validity confirmed by recent data demonstrating survival improvements. According to Novocure's December 2024 announcement regarding the Phase 3 PANOVA-3 trial, patients treated with TTFields plus chemotherapy achieved a median overall survival of 16.20 months compared to 14.16 months for chemotherapy alone, establishing device-based therapeutics as a vital component of modern multimodal care regimens.

Key Market Players

  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Getwell
  • Ipsen Biopharmaceuticals, Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Genentech USA, Inc.
  • AstraZeneca Plc

Report Scope

In this report, the Global Locally Advanced Pancreatic Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Locally Advanced Pancreatic Cancer Market, By Therapy

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Surgery

Locally Advanced Pancreatic Cancer Market, By Route of administration

  • Oral
  • Injectables
  • Others

Locally Advanced Pancreatic Cancer Market, By End-User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Locally Advanced Pancreatic Cancer Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Locally Advanced Pancreatic Cancer Market.

Available Customizations:

Global Locally Advanced Pancreatic Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Locally Advanced Pancreatic Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery)
    • 5.2.2. By Route of administration (Oral, Injectables, Others)
    • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Locally Advanced Pancreatic Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Route of administration
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Locally Advanced Pancreatic Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Route of administration
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Locally Advanced Pancreatic Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Route of administration
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Locally Advanced Pancreatic Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Route of administration
        • 6.3.3.2.3. By End-User

7. Europe Locally Advanced Pancreatic Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Route of administration
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Locally Advanced Pancreatic Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Route of administration
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Locally Advanced Pancreatic Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Route of administration
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Locally Advanced Pancreatic Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Route of administration
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Locally Advanced Pancreatic Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Route of administration
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Locally Advanced Pancreatic Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Route of administration
        • 7.3.5.2.3. By End-User

8. Asia Pacific Locally Advanced Pancreatic Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Route of administration
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Locally Advanced Pancreatic Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Route of administration
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Locally Advanced Pancreatic Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Route of administration
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Locally Advanced Pancreatic Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Route of administration
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Locally Advanced Pancreatic Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Route of administration
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Locally Advanced Pancreatic Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Route of administration
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Locally Advanced Pancreatic Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Route of administration
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Locally Advanced Pancreatic Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Route of administration
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Locally Advanced Pancreatic Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Route of administration
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Locally Advanced Pancreatic Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Route of administration
        • 9.3.3.2.3. By End-User

10. South America Locally Advanced Pancreatic Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Route of administration
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Locally Advanced Pancreatic Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Route of administration
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Locally Advanced Pancreatic Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Route of administration
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Locally Advanced Pancreatic Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Route of administration
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Locally Advanced Pancreatic Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Glaxosmithkline Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. Getwell
  • 15.5. Ipsen Biopharmaceuticals, Inc.
  • 15.6. Novartis Pharmaceuticals Corporation
  • 15.7. Pfizer Inc.
  • 15.8. Bayer HealthCare Pharmaceuticals, Inc.
  • 15.9. Genentech USA, Inc.
  • 15.10. AstraZeneca Plc

16. Strategic Recommendations

17. About Us & Disclaimer